Categories: News

FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign

MOMENCE, Ill., June 5, 2025 /PRNewswire/ — New research published in the International Journal of Molecular Sciences shows that vitAlign®, a proprietary and comprehensive healthy aging innovation from FutureCeuticals, delivers significant benefits for restoring cellular health and supporting a healthy immune response.

- Advertisement -

The study highlights vitAlign’s effectiveness in regulating cellular function and metabolic imbalances associated with immune stressors—from the seasonal cold and flu to more complex environmental and immune-related challenges.

- Advertisement -

Researchers evaluated the impact of a low, 50 mg dose of vitAlign in medically stable adults aged 40–55 recovering from a moderate course of COVID-19, as defined by CDC guidelines. The study compared vitAlign to a 1000 mg dose of Vitamin C, focusing on key markers and processes that directly impact immune and cellular health.

- Advertisement -

Results showed that vitAlign significantly reduced excessive reactive oxygen species (ROS) production in mitochondria and through the NOX2 and iNOS pathways—key mechanisms that influence immune and cellular function. Additionally, researchers observed increased levels of circulating, bioavailable nitric oxide, suggesting support for endothelial function and cardiovascular health. The authors noted that the increase in nitric oxide is likely attributable to vitAlign’s ability to regulate multiple pathways of ROS production.

- Advertisement -

Notably, vitAlign delivered measurable effects within 30 minutes, lasting up to three hours. In contrast, Vitamin C, which was used as a positive control, was administered at twenty times the dose and did not demonstrate comparable broad-spectrum activity.

- Advertisement -

“These findings build on over a decade of published clinical research establishing vitAlign as a significant cellular health innovation, now extended directly to immune function,” said J. Randal Wexler, FutureCeuticals’ General Counsel and Vice President of R&D. “Previously, we’ve shown that vitAlign improves cellular energy efficiency and helps restore metabolic balance, both acutely and over time.”

- Advertisement -

Wexler added, “These new results, which compare favorably to a well-known antioxidant like Vitamin C, reinforce vitAlign’s potential as a multi-faceted phytonutrient formula, providing broad support for healthy aging, cardiovascular health, and immune function. Our partners are excited about what this means for product innovation and their customers looking for daily cellular health support.”

- Advertisement -

About FutureCeuticals:
FutureCeuticals, Inc. is the developer of vitAlign and a leader in the research, development, and manufacture of plant-based powders and extracts for the functional food, beverage, and dietary supplement markets.

- Advertisement -

Logo – https://mma.prnewswire.com/media/2645826/FutureCeuticals_Logo.jpg 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/futureceuticals-inc-announces-peer-reviewed-publication-highlighting-cellular-health-and-immune-support-benefits-of-vitalign-302473687.html

- Advertisement -
PRNW Agency

Recent Posts

Litecoin Creator Charlie Lee Joins SilentSwap as Strategic Advisor to Advance Privacy Infrastructure for Digital Assets

Cryptocurrency Pioneer Brings Deep Technical Expertise and Vision for Financial Privacy to Next-Generation Cross-Chain Platform…

2 hours ago

IBM and Agassi Sports Entertainment Announce AI-Powered Platform to Advance Global Racquet Sports

Partnering to deliver a digital platform with AI-powered video coaching, premium content, and commercial experiences…

2 hours ago

Curonix Strengthens Executive Leadership with Appointment of Leading Medical Device Executive Russell Fleeger as Chief Financial Officer to Drive Next Stage of Growth

POMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Curonix LLC (“Curonix” or the “Company”),…

5 hours ago

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

November 05, 2025 08:00 ET  | Source: LENZ Therapeutics, Inc. VIZZTM (aceclidine ophthalmic solution) 1.44%…

5 hours ago

Survey from White Clay Finds Two-thirds of Customers Do Not Feel Truly Known by Their Primary Financial Institution

Data shows relationship gap between financial institutions and their customers is holding strong LOUISVILLE, Ky.--(BUSINESS…

5 hours ago

Motus Recognized as a 2025 Inc. Power Partner Award Winner

The annual list recognizes the leading B2B companies that have proven track records of supporting…

5 hours ago